Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
- PMID: 33008623
- DOI: 10.1016/j.jhep.2020.07.038
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".J Hepatol. 2021 Jan;74(1):246-247. doi: 10.1016/j.jhep.2020.09.005. Epub 2020 Sep 26. J Hepatol. 2021. PMID: 32988659 No abstract available.
Comment on
-
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.J Hepatol. 2020 Nov;73(5):1037-1045. doi: 10.1016/j.jhep.2020.06.011. Epub 2020 Jun 16. J Hepatol. 2020. PMID: 32553667
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
